Publicaciones en las que colabora con ATANASIO PANDIELLA ALONSO (25)

2021

  1. Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer

    Frontiers in Oncology, Vol. 11

2019

  1. MEK5 promotes lung adenocarcinoma

    The European respiratory journal

2015

  1. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone

    Leukemia, Vol. 29, Núm. 3, pp. 705-714

2014

  1. NADPH oxidases as therapeutic targets in chronic myelogenous leukemia

    Clinical Cancer Research, Vol. 20, Núm. 15, pp. 4014-4025

  2. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: Implications in myeloma progression and myeloma bone disease

    Oncotarget, Vol. 5, Núm. 18, pp. 8284-8305

2012

  1. CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype

    Haematologica, Vol. 97, Núm. 7, pp. 1110-1114

  2. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

    Leukemia, Vol. 26, Núm. 8, pp. 1862-1869

  3. Dasatinib as a bone-modifying agent: Anabolic and anti-resorptive effects

    PLoS ONE, Vol. 7, Núm. 4

2011

  1. Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response

    Haematologica, Vol. 96, Núm. 5, pp. 687-695

2009

  1. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors

    Leukemia, Vol. 23, Núm. 8, pp. 1515-1527

  2. Zalypsis: A novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks

    Blood, Vol. 113, Núm. 16, pp. 3781-3791

2008

  1. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

    Cancer Research, Vol. 68, Núm. 13, pp. 5216-5225

  2. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings

    The Lancet Oncology, Vol. 9, Núm. 12, pp. 1157-1165

  3. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype

    Haematologica, Vol. 93, Núm. 1, pp. 57-66

2007

  1. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer

    Journal of Clinical Oncology, Vol. 25, Núm. 19, pp. 2656-2663

  2. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer

    Annals of Oncology, Vol. 18, Núm. 3, pp. 421-430

2006

  1. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines

    Blood, Vol. 107, Núm. 9, pp. 3575-3583

  2. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance

    Cancer Research, Vol. 66, Núm. 11, pp. 5781-5789

  3. Trastuzumab and antiestrogen therapy: Focus on mechanisms of action and resistance

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 29, Núm. 1, pp. 90-95

2005

  1. Bortezomib is an efficient agent in plasma cell leukemias

    International Journal of Cancer, Vol. 114, Núm. 4, pp. 665-667